Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 9/20 | 0.49 |
| ▸ | TP53 | P04637 | 6/20 | 0.46 |
| ▸ | MAPT | P10636 | 6/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7429739 | 0.93 | HTR6 (0.44) | HTR6TP53MAPTSMN1; SMN2CYP1A2 | |
| SCHEMBL6579518 | 0.84 | HTR6 (0.49) | HTR6TP53MAPTSMN1; SMN2CYP1A2 | |
| SCHEMBL6882777 | 0.77 | ALDH1A1 (0.55) | SMN1; SMN2CYP3A4KDM4EALDH1A1GAA | |
| SCHEMBL6881406 | 0.76 | ALDH1A1 (0.55) | TP53SMN1; SMN2CYP3A4KDM4EALDH1A1 | |
| Bicarbonate SCHEMBL6881965 | 0.74 | ALDH1A1 (0.54) | SMN1; SMN2KDM4EALDH1A1GAAHPGD | |
| SCHEMBL6778063 | 0.73 | KDM4E (0.44) | HTR6TP53MAPTSMN1; SMN2CYP1A2 | |
| SCHEMBL7391317 | 0.73 | MMP12 (0.47) | HTR6TP53MAPTSMN1; SMN2CYP1A2 | |
| SCHEMBL6771728 | 0.73 | SMN1; SMN2 (0.52) | HTR6TP53MAPTSMN1; SMN2CYP1A2 | |
| Bicarbonate SCHEMBL6879664 | 0.73 | ALDH1A1 (0.55) | SMN1; SMN2CYP3A4KDM4EALDH1A1GAA | |
| SCHEMBL6577297 | 0.72 | HTR6 (0.47) | HTR6CYP1A2CYP3A4CYP2C19KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1100792-B1 | TRICYCLIC SULFONAMIDES AND THEIR DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | WARNER LAMBERT CO (US) | 2004-03-17 | — | — | EP | disclosed |
| US-6555535-B2 | Anticancer, antiarthritic, and antiinflammatory agents, and heart failure treatment | WARNER-LAMBERT COMPANY | 2003-04-29 | — | — | US | disclosed |
| US-6492422-B2 | GELATINASE A, COLLAGENASE-3, AND STROMELYSIN-1 INHIBITOR AND USEFUL FOR THE TREATMENT OF MULTIPLE SCLEROSIS, ATHEROSCLEROTIC PLAQUE RUPTURE, AROTIC ANEURYSM, HEART FAILURE, RESTENOSIS, PERIODONTAL DISEASE OR AUTOIMMUNE | WARNER-LAMBERT COMPANY | 2002-12-10 | — | — | US | disclosed |
| US-20020169164-A1 | Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases | WARNER-LAMBERT COMPANY | 2002-11-14 | — | — | US | disclosed |
| US-20020156071-A1 | Tricyclic biphenyl sulfonamide matrix metalloproteinase inhibitors | O'BRIEN PATRICK MICHAEL (US) | 2002-10-24 | — | — | US | disclosed |
| EP-1233018-A2 | Tricyclic biphenyl sulfonamide matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2002-08-21 | — | — | EP | disclosed |
| US-6420408-B1 | MULTIPLE SCLEROSIS, ATHEROSCLEROTIC PLAQUE RUPTURE, CARDIOVASCULAR DISORDERS, RESTENOSIS, PERIODONTAL DISEASE, AUTOIMMUNE OR INFLAMMATORY DISORDERS, ALZHEIMER'S DISEASE, AMYOTROPHIC LATERAL SCLEROSIS, CEREBRAL AMYLOID ANGIOPATHY, | WARNER-LAMBERT COMPANY | 2002-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156071-A1 | Tricyclic biphenyl sulfonamide matrix metalloproteinase inhibitors | MMP1, MMP9, MMP3 | HTR6 2064/4885TP53 2595/4885MAPT 4666/4885 |
| US-20020169164-A1 | Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases | MMP3, MMP12, MMP8 | HTR6 3596/4885TP53 3812/4885MAPT 1220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.